Ten patients, zero returns so far: a living cell therapy is standing guard after stomach-cancer surgery

For people whose stomach cancer is caught at an advanced local stage, surgery is only half the battle — the cancer comes back in roughly a third of high-risk patients within two years. In China, researchers tried something new after surgery: satri-cel, a treatment made from a patient's own immune cells, collected, re-trained in a lab to hunt a protein called Claudin18.2 that sits on these cancer cells, and given back as a one-time infusion. In early results shared at the ESMO cancer congress in Madrid, all 10 patients who received it — a group at especially high risk of the cancer returning — remain free of recurrence so far, with a 100% disease-free rate at 12 months, and one patient's blood test flipped from showing traces of leftover cancer to showing none. Side effects were mostly mild fevers and chills that settled in about four days. The group is small and the follow-up is early, and the results come from the maker's own announcement, as is standard for first trial readouts — larger studies will decide whether the guard holds. (This therapy is already approved in China for later-stage stomach cancer; this trial asks whether it can protect people earlier, right after surgery.)

SDG 3 · Good health and well-being — Mechanism: tech innovation